Gastric Cancer Market

The gastric cancer market was valued at USD 4.9 billion in 2023, driven by the increasing incidence of gastric cancer and increase in clinical trials and research activities across the 8 major markets. The market is projected to grow at a CAGR of 13% during the forecast period 2024-2032, with its value expected to reach USD 14.5 billion by 2032.

Gastric Cancer Market Analysis

Gastric cancer, or stomach cancer, primarily develops from the mucosal lining, with adenocarcinoma being the most common form. Often asymptomatic in its early stages, it is frequently diagnosed late. Key risk factors include Helicobacter pylori infection, a diet high in smoked or salted foods, smoking, and genetic predispositions like CDH1 mutations. As the disease progresses, symptoms such as weight loss, indigestion, nausea, and gastrointestinal bleeding may appear. Diagnosis involves endoscopy, imaging, and biomarker testing. Treatment depends on the stage and includes surgery, chemotherapy, targeted therapy, immunotherapy, and radiation, often in combination for advanced cases.

Market Drivers

• Rising Global Prevalence of Gastric Cancer: The increasing incidence of gastric cancer globally, especially in high-risk areas like East Asia, is a significant driver for market growth. As the number of cases rises, there is a greater demand for advanced treatment options, including surgical procedures, targeted therapies, and immunotherapies, all contributing to market expansion. This growing patient pool is placing considerable pressure on healthcare systems to develop and implement more effective diagnostic and therapeutic solutions.
• Advancements in Diagnostic Technologies: Significant progress in diagnostic tools, such as endoscopic techniques, biomarker testing, and precision imaging, has greatly enhanced the early detection of gastric cancer. Early diagnosis is critical in improving survival rates, as treatment in the early stages of the disease is far more effective. These technological advancements have also led to the increased adoption of precision medicine, which tailors treatments to individual patients, further driving market demand for personalised therapies.
• Ageing Population: The global ageing population is a key driver for the gastric cancer market. With people living longer, there is a growing prevalence of cancer, particularly in those aged 50 and older. This demographic shift is expected to lead to a sustained rise in gastric cancer cases, necessitating the development of improved treatment options that can be effectively administered to elderly patients, who often have additional comorbidities requiring specialised care.
• Increased Focus on Immunotherapy: The growing adoption of immunotherapy in oncology, particularly with drugs such as checkpoint inhibitors, has opened up new avenues for treating gastric cancer, especially in patients with advanced or metastatic disease. Immunotherapy offers a promising alternative to traditional treatments like chemotherapy and is becoming a cornerstone in the treatment of various cancer types, including gastric cancer, thus driving demand for innovative immunotherapeutic solutions.

Challenges

• Late-Stage Diagnosis: Gastric cancer is frequently diagnosed in its later stages due to non-specific early symptoms, such as indigestion and stomach discomfort, which are often mistaken for less severe conditions. This delayed diagnosis reduces the effectiveness of treatment options and contributes to lower survival rates. The late detection of the disease remains a significant challenge for the market, as it limits the success of potentially curative treatments.
• Limited Public Awareness: Despite increasing incidences of gastric cancer in some regions, public awareness of the disease remains low. Many patients are unaware of the risk factors or the importance of early screening, particularly in countries where gastric cancer is less prevalent. This lack of awareness hinders early detection efforts and reduces the potential for early intervention, thereby limiting the effectiveness of treatment and the overall market growth.
• Adverse Side Effects of Treatment: Many of the existing treatments for gastric cancer, including chemotherapy and radiotherapy, are associated with significant side effects, such as nausea, immune system suppression, and fatigue. These adverse effects often lead to poor patient adherence, reducing the overall success of treatment and presenting a challenge for market players to develop therapies that are both effective and better tolerated.
• Regulatory Hurdles and Reimbursement Issues: Varying regulatory frameworks across different countries and regions pose challenges for companies looking to launch new treatments. The complexity of securing regulatory approvals, combined with the difficulties in obtaining reimbursement for high-cost therapies, can slow down the introduction of novel drugs, limiting market growth, especially in regions with stringent healthcare regulations.

Future Opportunities

• Development of Precision Medicine: Precision medicine, which involves tailoring treatment to the genetic profile of a patient’s cancer, is emerging as a transformative approach in gastric cancer treatment. With ongoing research into the molecular mechanisms of gastric cancer, there is significant potential for the development of targeted therapies that provide more effective and personalised treatment options, thus driving the market growth.
• Collaborative Partnerships and Strategic Alliances: Increasing collaboration between pharmaceutical companies, research institutions, and academic centres is fostering innovation in the gastric cancer market. These partnerships are aimed at accelerating the development of new treatments, sharing research insights, and improving patient access to advanced therapies. Such strategic alliances present significant opportunities for market expansion and innovation.
• Growth in Early Detection Programmes: The rising emphasis on early detection of gastric cancer through government-led screening programmes and public health initiatives provides a major opportunity for market growth. Early-stage cancer detection significantly improves the chances of successful treatment, thereby increasing the demand for diagnostic tools and treatments aimed at early intervention.
• Advances in Minimally Invasive Surgical Techniques: The development of minimally invasive surgical techniques, such as laparoscopic and robotic surgeries, offers a less invasive treatment option for patients with early-stage gastric cancer. These techniques are associated with shorter recovery times, fewer complications, and improved patient outcomes, which is driving their adoption in hospitals and clinics, presenting a significant growth opportunity for the market.

Gastric Cancer Market Trends

The gastric cancer market is undergoing significant evolution, propelled by technological advancements and emerging treatment approaches. As ongoing research sheds light on the disease’s complexities, several important trends are emerging, which are expected to influence the future trajectory of this market.

• Rising Adoption of Targeted Therapies

There is a growing trend towards the adoption of targeted therapies in the treatment of gastric cancer. These therapies focus on specific genetic mutations or proteins involved in the growth of cancer cells, offering a more precise and less toxic treatment option compared to traditional chemotherapy. This shift is expected to continue as research into the molecular basis of gastric cancer progresses, leading to the development of new targeted drugs.

• Growing Popularity of Immunotherapy

Immunotherapy, particularly checkpoint inhibitors such as pembrolizumab, is gaining popularity as an effective treatment for patients with advanced or metastatic gastric cancer. This trend is being driven by the success of immunotherapy in improving survival rates and offering a new line of treatment for patients who have failed to respond to conventional therapies. As more immunotherapies receive approval, their use in gastric cancer treatment is expected to rise.

• Increasing Use of Artificial Intelligence in Diagnostics

The integration of artificial intelligence (AI) in diagnostic imaging and pathology is revolutionising the way gastric cancer is detected and monitored. AI algorithms can analyse imaging data with greater accuracy and speed than traditional methods, improving early detection and helping to guide treatment decisions. The growing use of AI in the healthcare sector is expected to drive demand for advanced diagnostic tools in the gastric cancer market.

• Surge in Clinical Trials for Combination Therapies

There is a growing focus on combination therapies that integrate chemotherapy, immunotherapy, and targeted treatments to improve patient outcomes. Clinical trials exploring the efficacy of these combinations are on the rise, reflecting a shift towards more comprehensive treatment approaches. The success of these trials is likely to lead to the widespread adoption of combination therapies in clinical practice.

• Emphasis on Early Detection Initiatives

Governments and healthcare organisations are increasingly focusing on initiatives aimed at promoting the early detection of gastric cancer. Public health campaigns and screening programmes are being implemented to increase awareness of the disease and encourage high-risk individuals to undergo regular screenings. This trend is expected to improve survival rates and boost demand for diagnostic and treatment services.

• Advancement in Surgical Techniques

The use of advanced surgical techniques, such as robotic-assisted surgery, is becoming more common in the treatment of gastric cancer. These techniques offer greater precision, reduce the risk of complications, and enhance patient recovery times. The trend towards minimally invasive procedures is expected to continue, as hospitals and clinics invest in new surgical technologies to improve patient care.

Gastric Cancer Market Segmentation

Market Breakup by Treatment Type

• Chemotherapy
• Immunotherapy
• Surgery
• Targeted Drug Therapy
• Others

The gastric cancer treatment market is shaped by a range of treatment options, with chemotherapy and surgery being the most widely used for early-stage cancer. Immunotherapy and targeted drug therapy are gaining traction for treating advanced or metastatic cancer, providing more personalised and effective treatment options. Other treatments, including radiotherapy and supportive care, play crucial roles in comprehensive cancer management, especially in palliative care settings.

Market Breakup by Cancer Type

• Adenocarcinoma
• Gastrointestinal Stromal Tumor
• Carcinoid Tumor
• Others

Adenocarcinoma dominates the market due to its high prevalence among gastric cancer cases. Other forms, such as gastrointestinal stromal tumors (GIST) and carcinoid tumours, represent smaller but significant segments, requiring specialised treatment approaches. The presence of diverse cancer types within this market necessitates a wide range of diagnostic and therapeutic solutions, which increases the complexity and size of the market.

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Oral treatments, such as targeted therapies and certain chemotherapies, are increasingly popular due to their convenience and ease of administration. Parenteral administration remains essential, particularly for therapies like immunotherapy and advanced chemotherapy that require intravenous delivery. Other emerging routes, including intraperitoneal drug delivery, are being explored to enhance treatment efficacy in advanced cases.

Market Breakup by End User

• Hospitals and Clinics
• Diagnostic Centers
• Research Laboratories
• Others

Hospitals and clinics form the largest segment, driven by their advanced facilities and ability to manage complex cases with multi-disciplinary teams. Clinics are playing a growing role in providing outpatient cancer care, offering convenient, specialised treatment options. Diagnostic centres are critical for early detection and monitoring, benefiting from advancements in imaging and biomarker technologies. Research laboratories drive innovation, contributing to the development of novel therapies and pushing the market forward. The other category includes specialised cancer centres and home care services, which are gaining importance as personalised treatment options expand.

Market Breakup by Region

• United States
• EU-4 and the United Kingdom

o Germany

o France

o Italy

o Spain

o United Kingdom

• Japan
• India

The United States remains the largest market, supported by high healthcare spending and a strong focus on cancer research and development. In Europe, the EU-4 and the UK are key markets, driven by government initiatives and advancements in healthcare infrastructure. Japan continues to be a significant market due to its high incidence of gastric cancer, while India represents an emerging market, with its growing healthcare sector and increasing awareness of cancer care.

Gastric Cancer Market Competitive Landscape

The competitive landscape of the gastric cancer market is highly dynamic, with leading pharmaceutical companies such as AstraZeneca, Pfizer, Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Celltrion, AbbVie Inc., and GSK plc playing prominent roles. These companies are actively engaged in expanding their portfolios with novel therapies, particularly in the fields of immunotherapy and targeted treatments, which are gaining significant market share. Strategic collaborations, mergers, acquisitions, and licensing agreements are key strategies, aimed at accelerating innovation and enhancing patient outcomes. Ongoing clinical trials and the development of combination therapies are expected to shape the market’s future, improving access to advanced treatments.

Key Questions Answered in the Report

• What is the current and projected growth of the gastric cancer treatment market globally and by region?
• What are the key challenges affecting the development and adoption of advanced gastric cancer treatments?
• What are the primary drivers contributing to the increasing demand for gastric cancer therapies?
• How are emerging trends like immunotherapy and targeted therapies influencing the treatment landscape for gastric cancer?
• What role does the ageing population play in driving the growth of the gastric cancer market?
• How will advancements in diagnostic technologies, such as precision imaging and biomarker identification, impact the market?
• How are hospitals and clinics adapting to the rising demand for advanced gastric cancer treatments?
• What opportunities exist for market growth in emerging regions, such as India and Southeast Asia?
• How do regulatory and reimbursement hurdles across different regions affect the introduction of novel gastric cancer therapies?
• How are pharmaceutical companies leveraging collaborations and strategic alliances to accelerate the development of gastric cancer treatments?
• What impact is precision medicine expected to have on the future of gastric cancer treatment and patient outcomes?
• How are AI and other advanced technologies transforming the diagnostic processes for early detection of gastric cancer?

Key Benefits for Stakeholders

• The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the gastric cancer market from 2017-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the gastric cancer market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the gastric cancer industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

This product will be delivered within 5-7 business days.